New EU regulations aim to speed up health technology assessments (HTAs), but the pharma industry raises logistical concerns.

The biotech is still well-funded, ending the third quarter of 2024 with more than $154 million in cash after completing a $101 million Series C at the end of 2023 and having raised around $487 ...

Microsoft’s AI integration strengthens its position. Read why MSFT stock remains a solid buy despite the impact of DeepSeek’s ...

Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

The company, helmed by BioNTech alums, is developing therapies aimed at dermatological, respiratory and gut-related ...

Biotech stocks are in the eye of the storm as the world recovers from the global pandemic. Government institutions and professional traders are banking on biotech stocks to continually develop a ...